The role of CD28-mediated signals in programming and reprogramming of mouse and human memory and induced regulatory T cells
The role of CD28-mediated signals in programming and reprogramming of mouse and human memory and induced regulatory T cells
批准号:
245011612
负责人:
Privatdozent Dr. Niklas Beyersdorf, since 10/2017
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2014
资助国家:
德国
项目状态:
已结题
起止时间:
2013-12-31 至 2018-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Upon appropriate stimulation, naive T cells express certain transcription factors such as T-bet or Gata-3 which guide their differentiation into functionally polarised complementary effector/memory populations. These cells belonging to the Th1, Th2 or to the more recently identified Th17 lineages are then thought to cross-regulate each other. However, there is now a substantial body of evidence for lineage plasticity meaning that e.g. Th2 cells may also acquire properties of Th1 cells. While the role of CD28-mediated co-stimulation is well documented during primary differentiation of naive T cells into effector/memory cells, the impact of CD28 stimulation on the reprogramming of effector and memory T cells is so far largely unknown. Moreover, induced Foxp3+ regulatory T cells, which bear great therapeutic potential, also display a high degree of plasticity in vivo depending on the disease model studied. In the experiments proposed herein we would, therefore, like to address the impact of CD28 stimulation on the reprogramming of fully differentiated mouse and human T cells in greater detail. To this end we will not only use CD28-specific reagents blocking ligand binding but also the novel inducible CD28-deleter mouse strain CD28-/flox, rosa(CreERT2) (iCD28k.o.) to study T cell reprogramming in vitro and during antigen-driven immune responses in vivo. We believe that the scheduled experiments will not only provide deeper insights into T cell differentiation in general but will also help to develop novel therapeutic strategies for humans who, in contrast to cleanly housed laboratory mice, contain large populations of fully differentiated memory T cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
LncRNA GAS5调控RUNX3/CD80/CD28轴促进甲状腺癌免疫激活的分子机制研究
-
批准号:2025JJ70535
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:刘渊
-
依托单位:
共信号受体PD-1和CD28通过相分离调控T细胞激活的分子机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:陈辉
-
依托单位:
PD-1/PD-L1通过CD28/Nur77/mTOR在耗竭性样CD8+ TRM介导病毒性肺纤维化中的分子机制及干预研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:53万元
-
批准年份:2022
-
负责人:王峥
-
依托单位:
BACH2介导的CD28表达改变在急性T淋巴细胞白血病发生发展及耐药反应中的机制研究
-
批准号:82270188
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:张寒
-
依托单位:
针刺调控CTLA-4/CD28协同刺激途径维持外周Treg稳态改善VD神经炎症反应的效应及机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:56万元
-
批准年份:2021
-
负责人:张雪竹
-
依托单位:
儿童哮喘中LCK通过促进AP-1/ETS1协同转录调控CD28表达影响Th1/Th2细胞平衡的机制研究
-
批准号:82100030
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:王天玥
-
依托单位:
PD1/CD28或IL4/IL7R嵌合体修饰的热点突变特异性TCR-T细胞治疗结直肠癌的效果评价及机制研究
-
批准号:82003264
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:谭琴
-
依托单位:
CD28调控naïveT细胞活化在放疗联合CTLA-4抑制剂诱导远隔效应中的作用及机制研究
-
批准号:82003229
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:夏凡
-
依托单位:
CD28共刺激信号调控Th17/Tfh细胞分化进而双向调节RA-FLS促炎/趋化功能并参与RA发病的机制研究
-
批准号:2020A151501039
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2020
-
负责人:毋静
-
依托单位:
NOD小鼠共刺激分子ICOS与CD28缺失导致CD4+ T细胞向炎性Th2 分化的机制
-
批准号:81901573
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2019
-
负责人:贺乐
-
依托单位: